De novo lupus nephritis (LN) is a rare complication in renal transplantation recipients. We present the clinical manifestations of de novo LN in a 12-year-old boy who received a cadaveric renal transplant. The cause of end-stage renal disease was prune belly syndrome with renal dysplasia. His immunosuppressive drugs included tacrolimus, mycophenolate sodium, and prednisolone. After 3 years of treatment, he developed nephrotic syndrome (NS) without other symptoms of systemic lupus erythematosus (SLE). The renal pathology of the transplanted kidney showed suspicious acute cellular rejection and LN World Health Organization class IV-G (A/C). Antinuclear antibody was positive, but anti-dsDNA and anti-Smith were negative. The serum complements were initially normal. Pulse methylprednisolone was given and the dosages of all immunosuppressive drugs increased; notwithstanding, his edema and hypoalbuminemia worsened. Repeated biopsy of the transplanted kidney was done. A full-house pattern was documented under immunofluorescent examination which confirmed LN WHO class IV-G (A/C) without evidence of rejection. He then developed macrophage-associated hemophagocytic syndrome and cytomegalovirus pneumonia. He ultimately developed pulmonary hemorrhage and died owing to severe pneumonia. De novo LN should be considered in renal transplant recipients with new onset of NS despite there not being any other clinical manifestations of SLE.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2013.12.023 | DOI Listing |
Int J Biol Macromol
December 2024
State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; Hubei Jiangxia Laboratory, Wuhan, Hubei 430200, China. Electronic address:
TNFα inhibitors have been successfully developed and used in the clinical treatment of autoimmune disorders. However, the use of TNFα blockade may be accompanied by side effects. The cases of bacterial and viral infections, lymphoproliferative disorders, and anti-TNFα-induced lupus, have been reported among the rheumatoid arthritis or Crohn's disease patients treated with TNFα blockers.
View Article and Find Full Text PDFCurr Rheumatol Rev
December 2024
Specialist Dermatologist, Department of Dermatology, Qassimi Hospital Sharjah.
Background: Systemic Lupus Erythematosus (SLE) (C1) is a disease with multi-organ involvement that can have a variety of cutaneous manifestations in 76% of cases during the disease. Less than 1% of these patients are diagnosed with confirmed bullous systemic lupus erythematosus (C1). Given the wide differential diagnosis of a bullous lesion, it is imperative to reach a conclusive diagnosis as it can have a direct impact on the course of management of the disease.
View Article and Find Full Text PDFHeliyon
October 2024
Universidad Icesi, CIRAT: Centro de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Calle 18 No. 122 -135, Cali, Colombia.
Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple systems and organs, including the central and peripheral nervous systems. Papilledema and idiopathic intracranial hypertension, in the absence of space-occupying lesions or other detectable causes, is a rare manifestation. We report the case of a young woman with chronic headache, papilledema, and intracranial hypertension on examination, in whom a de novo diagnosis of systemic lupus erythematosus and class V lupus nephritis was made.
View Article and Find Full Text PDFJAMA Dermatol
December 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!